Action plans and policy papers

Augustin M, Bewley A, Brüggen MC, de Bruin-Weller MS, Ezzedine K, Ferrucci SM, Gkalpakiotis S, Herranz P, Johansson EK, Kampe T, Lapeere H, Legat FJ, Rehbinder EM, Szepietowski JC, Torres T, Vestergaard C, Werfel T, Domenech A, Massana E, Koscielny V, Narayanan S, Kasujee I, Gutermuth J (2025)
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol
BMJ Open, 15 (7), e102155
DOI 10.1136/bmjopen-2025-102155, PubMed 40645621

Melsom T, Brobak KM, Norvik JV, Enoksen IT, Rinde L, Jenssen TG, Eriksen BO (2025)
Iohexol clearance, but not estimated GFR, reveals a steeper GFR decline in patients with prediabetes
Kidney Int (in press)
DOI 10.1016/j.kint.2025.06.019, PubMed 40645290

Sabanovic H, Pauling JD, Baron M, Clemens L, Del Galdo F, Denton CP, Distler O, Frech T, Hoffmann-Vold AM, Hudson M, Khanna D, Maltez N, Medsger TA, Merkel PA, Nikpour M, Pope J, Steen VD, Stevens W, Volkmann ER, Ross L (2025)
'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis
Rheumatology (Oxford) (in press)
DOI 10.1093/rheumatology/keaf377, PubMed 40644620

Bjerkreim H, Thorbjørnsen BL, Nærland T, Drolsum L, Kristianslund O (2025)
Nationwide study of the association between keratoconus and autism spectrum disorder
J Cataract Refract Surg (in press)
DOI 10.1097/j.jcrs.0000000000001740, PubMed 40643180